•
Jun 30, 2022

ClearPoint Neuro Q2 2022 Earnings Report

Reported record quarterly revenue and biologics and drug delivery business led the way.

Key Takeaways

ClearPoint Neuro reported a record quarterly revenue of $5.2 million, a 52% year-over-year increase. The biologics and drug delivery business became the largest segment with product and service revenue growing at more than 70%. The company reaffirmed its full year 2022 revenue outlook of between $21.0 and $22.0 million.

Reported record quarterly revenue of $5.2 million, a 52% year-over-year increase.

Increased biologics and drug delivery revenue to $2.4 million, a 73% year-over-year increase.

Added multiple new biologics and drug delivery partners in the quarter to bring the total to more than 45.

Installed four additional systems in the quarter bringing the total to 8 new installations year-to-date.

Total Revenue
$5.2M
Previous year: $3.41M
+52.4%
EPS
-$0.18
Previous year: -$0.17
+5.9%
Gross Profit
$3.26M
Previous year: $2.28M
+43.0%
Cash and Equivalents
$23.5M
Previous year: $61.5M
-61.7%
Free Cash Flow
-$5.06M
Previous year: -$3.68M
+37.3%
Total Assets
$60.2M
Previous year: $72.3M
-16.7%

ClearPoint Neuro

ClearPoint Neuro

ClearPoint Neuro Revenue by Segment

Forward Guidance

The Company reaffirms its full year 2022 revenue outlook of between $21.0 and $22.0 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income